Technical Analysis for OVID - Ovid Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Flat | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| NR7 | Range Contraction | 3.00% | |
| Down 3 Days in a Row | Weakness | 3.00% | |
| 50 DMA Resistance | Bearish | 2.32% | |
| Earnings Movers | Other | 2.32% | |
| BB Squeeze Ended | Range Expansion | 2.32% | |
| 20 DMA Resistance | Bearish | 0.98% | |
| 50 DMA Resistance | Bearish | 0.98% | |
| Bollinger Band Squeeze | Range Contraction | 0.98% | |
| Earnings Movers | Other | 0.98% |
| Alert | Time |
|---|---|
| Rose Above 50 DMA | about 16 hours ago |
| Up 3% | about 16 hours ago |
| 10 DMA Resistance | about 20 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
| Rose Above Previous Day's High | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/03/2024
Ovid Therapeutics Inc. Description
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Disorders Neurological Disorders Epilepsy Urological Disorders Syndromes Genodermatoses Sedatives Fragile X Syndrome Rare Neurological Disorders Anticonvulsants
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.1389 |
| 52 Week Low | 2.57 |
| Average Volume | 223,861 |
| 200-Day Moving Average | 3.41 |
| 50-Day Moving Average | 3.10 |
| 20-Day Moving Average | 3.13 |
| 10-Day Moving Average | 3.08 |
| Average True Range | 0.16 |
| RSI (14) | 48.45 |
| ADX | 11.0 |
| +DI | 17.42 |
| -DI | 18.02 |
| Chandelier Exit (Long, 3 ATRs) | 2.97 |
| Chandelier Exit (Short, 3 ATRs) | 3.39 |
| Upper Bollinger Bands | 3.32 |
| Lower Bollinger Band | 2.95 |
| Percent B (%b) | 0.38 |
| BandWidth | 11.71 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.0105 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.29 | ||||
| Resistance 3 (R3) | 3.27 | 3.19 | 3.25 | ||
| Resistance 2 (R2) | 3.19 | 3.14 | 3.20 | 3.24 | |
| Resistance 1 (R1) | 3.14 | 3.11 | 3.17 | 3.16 | 3.23 |
| Pivot Point | 3.06 | 3.06 | 3.07 | 3.07 | 3.06 |
| Support 1 (S1) | 3.01 | 3.01 | 3.04 | 3.03 | 2.95 |
| Support 2 (S2) | 2.93 | 2.98 | 2.94 | 2.94 | |
| Support 3 (S3) | 2.88 | 2.93 | 2.93 | ||
| Support 4 (S4) | 2.90 |
